367 related articles for article (PubMed ID: 31669933)
1. Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions.
Levy-Mendelovich S; Livnat T; Barg AA; Kidon M; Brutman-Barazani T; Kenet G
Blood Cells Mol Dis; 2020 Feb; 80():102370. PubMed ID: 31669933
[TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
3. The management of hemophilia patients with inhibitors.
Nilsson IM
Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
[No Abstract] [Full Text] [Related]
4. Anaphylaxis in patients with hemophilia.
Jadhav M; Warrier I
Semin Thromb Hemost; 2000; 26(2):205-8. PubMed ID: 10919414
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
6. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.
Ljung R; Auerswald G; Benson G; Dolan G; Duffy A; Hermans C; Jiménez-Yuste V; Lambert T; Morfini M; Zupančić-Šalek S; Santagostino E
Eur J Haematol; 2019 Feb; 102(2):111-122. PubMed ID: 30411401
[TBL] [Abstract][Full Text] [Related]
7. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
10. Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia.
Blumberg RS; Lillicrap D;
Blood; 2018 May; 131(20):2205-2214. PubMed ID: 29588277
[TBL] [Abstract][Full Text] [Related]
11. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
12. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
13. Hemophilia in Iran.
Dorgalaleh A; Dadashizadeh G; Bamedi T
Hematology; 2016 Jun; 21(5):300-10. PubMed ID: 26914731
[TBL] [Abstract][Full Text] [Related]
14. Management of factor VIII inhibitors: evolution and current status.
Bloom AL
Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
[TBL] [Abstract][Full Text] [Related]
15. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
Franchini M; Coppola A; Tagliaferri A; Lippi G
Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
[TBL] [Abstract][Full Text] [Related]
16. Switching haemophilia products and inhibitor risk: a United States' perspective.
Nance D; Rodgers GM
Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
[No Abstract] [Full Text] [Related]
17. The current state of adverse event reporting in hemophilia.
van Vulpen LF; Saccullo G; Iorio A; Makris M
Expert Rev Hematol; 2017 Feb; 10(2):161-168. PubMed ID: 28013565
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
19. Recombinant clotting factors in the treatment of hemophilia.
Lee C
Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
[No Abstract] [Full Text] [Related]
20. The evolution of recombinant factor replacement for hemophilia.
Sankar AD; Weyand AC; Pipe SW
Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
